Attached files
file | filename |
---|---|
8-K - LIVE FILING - SERACARE LIFE SCIENCES INC | htm_42141.htm |
SeraCare Acknowledges Receipt of Unsolicited Proposal from MSMB Capital
MILFORD, MA., June 23, 2011 SeraCare Life Sciences, Inc. (NASDAQ: SRLS), a global life sciences company providing vital products and services to facilitate the discovery, development and production of human diagnostics and therapeutics, today acknowledged the receipt of an unsolicited offer from MSMB Capital proposing to purchase all of the outstanding shares of SeraCare for $4.25 per share. It is anticipated that the SeraCare Board of Directors will review the proposal in due course.
About SeraCare Life Sciences, Inc.:
SeraCare serves the global life sciences industry by providing vital products and services to
facilitate the discovery, development and production of human diagnostics and therapeutics. The
Companys innovative portfolio includes diagnostic controls, plasma-derived reagents and molecular
biomarkers, biobanking and contract research services. SeraCares quality systems, scientific
expertise and state-of-the-art facilities support its customers in meeting the stringent
requirements of the highly regulated life sciences industry.
Forward-Looking Statements:
This press release contains forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 about SeraCare Life Sciences, Inc. (SeraCare or the Company). All
statements regarding our future financial position, results of operations, cash flows, dividends,
financing plans, business strategy, budget, projected costs or cost savings, capital expenditures,
competitive positions, growth opportunities for existing products or products under development,
plans and objectives of management for future operations and markets for stock are forward-looking
statements. In addition, forward-looking statements include statements in which we use words such
as expect, believe, anticipate, intend, or similar expressions. Although we believe the
expectations reflected in such forward-looking statements are based on reasonable assumptions, we
cannot assure you that these assumptions will prove to have been correct, and actual results may
differ materially from those reflected in the forward-looking statements. Factors that could cause
our actual results to differ from the expectations reflected in the forward-looking statements in
this press release include, but are not limited to, prolonged impairment of sales from changes in
our sales organization, potential difficulties hiring sales personnel with the desired
qualifications, revenue shortfalls arising from customer transitions to new products,
unpredictability in large customer orders, failure to maintain proper inventory levels,
availability of financing, reductions or terminations of government or other contracts,
interruption in our supply of products or raw materials, actions of SeraCares competitors, changes
in the regulatory environment, delays in new product introductions, lack of market acceptance of
new products, decreased healthcare spending, reduced margins resulting from a shift in revenue
towards services, absence or loss of acquisition opportunities to higher bidders, potential failure
to complete any announced acquisition, and potential failure of any acquisition to produce expected
revenues, profits or synergies. Many of these factors are beyond our ability to control or predict.
Contacts:
Gregory A. Gould
Chief Financial Officer
SeraCare Life Sciences, Inc.
508-244-6400
Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060